参考文献/References:
[1] Smith U. Pioglitazone: mechanism of action [J]. International Journal of Clinical Practice, 2001, 121: 13-18.
[2] Lawrence J M, Reckless J P. Actos (pioglitazone): a new treatment for type 2 diabetes [J]. Hospital Medicine, 2001, 62(7): 411-416.
[3] 秦宗会, 沈光明, 刘於生, 等. 氯酚红分光光度法测定盐酸吡格列酮 [J]. 分析试验室, 2007, 27(10): 15-18.
[4] 杨玉芳, 周燕文. 紫外分光光度法测定盐酸吡格列酮片的含量 [J]. 中国药师, 2007, 10(4): 354-355.
[5] 秦宗会, 谭蓉, 谢兵, 等. 盐酸吡格列酮与曙红Y相互作用的荧光和共振光散射光谱研究 [J]. 化学通报, 2010, 73(2): 166-172.
[6] 张敏波, 张叶萍.盐酸吡格列酮的HPLC测定 [J]. 中国医药工业杂志, 2003, 34(8): 405-407.
[7] Pattana Sripalakit, Penporn Neamhom, Aurasorn Saraphanchotiwitthaya. High- performance liquid chromatographic method for the determinationof pioglitazone in human plasma using ultraviolet detection and its application to a pharmacokinetic study [J]. Journal of Chroma- tography B, 2006, 843: 164-169.
[8] 戴俊东, 金笃嘉, 刘玉玲. RP-HPLC法测定盐酸吡格列酮含量及有关物质的方法学研究 [J]. 药物分析杂志, 2001, 21(1): 36-39.
[9] Maeshiba Y, Kiyota Y, Yamashita K, et al. Disposition of the new antidiabetic agent pioglitazone in rats, dogs, and monkeys [J]. Arzneimittel- Forschung, 1997, 47(1): 29-35.
[10] Zhongping John Lin, Ji Weihua, Daksha Desai-Krieger, et al.Simultaneous determi-nation of pioglitazone and its two active metabolites in human plasma by LC-/MS/MS [J]. Journal of Pharmaceutical and Biomedical Analysis, 2003, 33: 101-108.
相似文献/References:
[1]卫世乾,贠嫣茹,张立科.紫外-可见光度法测定茶碱缓释片中茶碱的研究[J].江西师范大学学报(自然科学版),2012,(02):205.
WEI Shi-qian,YUN Yan-ru,ZHANG Li-ke.The Determination of Theophylline in Sustained-Release Tablet with the UV-Vis Spectrophotometry[J].Journal of Jiangxi Normal University:Natural Science Edition,2012,(02):205.